US 12,295,921 B2
Epinephrine spray formulations
Steven Hartman, Beverly Hills, CA (US); Michelle Lobel, Beverly Hills, CA (US); Matthew P. Robben, Pittsford, NY (US); Kenneth L. Dretchen, Gaithersburg, MD (US); and Michael Mesa, Boyds, MD (US)
Assigned to Bryn Pharma, LLC, Raleigh, NC (US)
Filed by Bryn Pharma, LLC, Raleigh, NC (US)
Filed on May 6, 2021, as Appl. No. 17/313,885.
Application 17/313,885 is a continuation of application No. 16/930,408, filed on Jul. 16, 2020, granted, now 11,723,884.
Application 16/930,408 is a continuation of application No. 16/864,183, filed on May 1, 2020, granted, now 10,925,841, issued on Feb. 23, 2021.
Application 16/864,183 is a continuation of application No. 16/355,525, filed on Mar. 15, 2019, granted, now 10,688,044, issued on Jun. 23, 2020.
Claims priority of provisional application 62/810,261, filed on Feb. 25, 2019.
Claims priority of provisional application 62/747,048, filed on Oct. 17, 2018.
Claims priority of provisional application 62/712,678, filed on Jul. 31, 2018.
Claims priority of provisional application 62/663,100, filed on Apr. 26, 2018.
Claims priority of provisional application 62/644,834, filed on Mar. 19, 2018.
Prior Publication US 2021/0361594 A1, Nov. 25, 2021
Int. Cl. A61K 31/137 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/12 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/38 (2006.01); A61M 11/00 (2006.01); A61M 15/08 (2006.01); A61P 37/08 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 9/0043 (2013.01); A61K 9/0078 (2013.01); A61K 9/08 (2013.01); A61K 9/12 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/20 (2013.01); A61K 47/38 (2013.01); A61M 11/007 (2014.02); A61P 37/08 (2018.01); A61M 15/08 (2013.01); A61M 2205/3553 (2013.01)] 27 Claims
 
1. A nasal delivery device adapted for delivery of a pharmaceutical nasal spray formulation into a nostril of a human subject, the nasal delivery device comprising:
a vial containing from about 125 μL to about 250 μL of the pharmaceutical nasal spray formulation;
a cannula;
a rubber stopper; and
a plunger,
wherein the pharmaceutical nasal spray formulation comprises
(a) from about 1% to about 10% (w/w) of epinephrine, or a pharmaceutically acceptable salt thereof, in water;
(b) from about 0.01% to about 0.1% (w/w) of sodium bisulfite or sodium metabisulfite;
(c) chlorobutanol or chlorobutanol hemihydrate; and
(d) one or more of an absorption enhancer, a viscosity modifier, a buffering agent, an isotonicity agent,
wherein the pharmaceutical nasal spray formation has a weight ratio of the epinephrine or pharmaceutically acceptable salt thereof to the chlorobutanol or chlorobutanol hemihydrate of about 12:1 to about 30:1;
wherein the rubber stopper is configured to occlude an opening of the vial, and the cannula is configured to pierce the rubber stopper when the plunger applies sufficient force to the cannula; and
wherein the nasal delivery device is configured to administer the pharmaceutical nasal spray formulation into a nostril of a human subject as one or two nasal sprays.